At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Antroquinonol +1 moredrug
Likely dose
Antroquinonol 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Double Blind, Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
In Brief
A Phase 2 clinical trial evaluating Antroquinonol and placebo for Hyperlipidemias. Completed, enrolled 120 participants across 6 sites.
Detailed Summary
Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemias
CountriesTaiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMay 2016
Primary CompletionSep 2018
Study CompletionMar 2019
TodayJul 2026
First PostedMar 25, 2016
Enrollment StartMay 1, 2016
Primary CompletionSep 27, 2018
Study CompletionMar 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.3 years ago
Interventions
Antroquinonoldrug
Antroquinonol will be provided as capsules of 50 mg
placebodrug
The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)